Tracking Excipients - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Tracking Excipients
A review of recent product innovations, policy developments, and growth prospects in the excipients market.


Pharmaceutical Technology
Volume 33, Issue 4, pp. 44-51

Analytical tools to support formulation development are also an important part of innovation. In March 2009, Paraytec (York, England) introduced ActiPix Dissolution Imager, a quantitative ultraviolet (UV) area imaging system to provide real-time imaging of pharmaceutical tablet dissolution. The company says that the product offers an alternative to using terahertz spectroscopic imaging and magnetic resonance imaging to secure data needed to evaluate drug-release processes. The instrument consists of a specially designed tablet holder that is placed inside the UV imaging system to enable real-time recording and review of data. When liquid flows over the surface of the formulation, the release of the active ingredient can be quantitatively monitored directly at the tablet surface. Paraytec is a scientific-instrument company that was formed as a spinout from the chemistry department at the University of York.

Shaping the excipient landscape

Increased globalization and strategies for securing the supply chain are important issues for excipient producers. The International Pharmaceutical Excipients Council (IPEC) expanded into China in July 2008 with the formation of IPEC–China. IPEC–China consists of manufacturers, distributors, and users of excipients. IPEC–China expects to work with China's State Food and Drug Administration in establishing standards for excipients, according to an IPEC–China 2008 press release.

IPEC is also considering a proposal to create a multiregional body, the IPEC Federation, which will provide advocacy and promote quality in excipients globally, according to recent information from IPEC Europe. The vision of the IPEC Federation would be to promote quality, safety, and functionality of excipients and to ensure that new excipients introduced into the market meet global standards. The federation would also seek to harmonize drug approval, technical, and pharmacopoeial standards and ensure that safe and effective dosage forms are circulated in the global supply chain. To meet these goals, the proposed federation would develop, implement, and promote voluntary, harmonized guidance and other programs for the pharmaceutical industry to ensure that excipients used in finished drug products meet appropriate standards for quality, safety, and functionality throughout the manufacturing and distribution process. The federation would collaborate with regulatory authorities in adopting scientifically suitable, risk-based, and global regulatory and compendial standards for excipients (1).

QbD will continue to play an important role in excipient usage. The goal of QbD is to improve process understanding, which includes the functional effects that excipients have on the drug-manufacturing process as well as understanding the process variability that may arise with an excipient in a formulation (2). As part of its ongoing Excipient Technical Applications Initiative, IPEC–Americas formed a working committee, the Quality by Design Product Development Committee, to consider issues relating to excipients in QbD. Some issues relating to excipients and QbD include the following:

  • The proper selection and use of excipient performance tests
  • The role of pharmacopeial monographs in meeting changing requirements
  • Developing robust formulations according to QbD and process analytical technology
  • Reducing barriers to excipient user–supplier collaboration to build on the shared knowledge base.

Nanotechnology is also an emerging issue in formulation development. In March 2009, the US Food and Drug Administration launched an initiative with the Alliance for NanoHealth (ANH). ANH and FDA cosponsored a scientific workshop, the FDA-ANH Nanotechnology Initiative Scientific Workshop, to obtain feedback from stakeholders in industry, the federal government, and academia to identify key scientific and translational challenges in nanoengineered medical product development. A goal of the workshop was to develop and publish a short list of existing translational gaps and the key elements needed to bridge these gaps, according to ANH. Member institutions of ANH include the Baylor College of Medicine, the University of Texas M.D. Anderson Cancer Center, Rice University, the University of Houston, the University of Texas Health Science Center at Houston, Texas A&M Health Science Center, University of Texas Medical Branch, and the Methodist Hospital Research Institute.

Market growth and segments

As these issues evolve, moderate growth is projected for the global excipient market, which was valued at $3.5 billion in 2006, according to BCC Research (3, 4). The market is expected to increase at a compound annual growth rate (CAGR) of 3.8% through 2011, when it will reach $4.3 billion. The global excipients market is broken down into three major segments: organic chemicals, inorganic chemicals, and United States Pharmacopeia (USP) water.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here